invicro
(2)
Jack Hoppin
Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.
Bill Cupelo
Bill Cupelo is the Chief Business Officer of Ratio Therapeutics, a Boston-based biotech building targeted radiopharmaceuticals that aim to both image and treat cancer. A chemist by training who learned to sell science, he spent more than a decade at imaging CRO Invicro, climbing from software product manager to head of sales, before bringing his sponsor-side, science-first mindset to Ratio's pipeline of alpha-emitting radioligand therapies. He also serves as Treasurer of the Massachusetts Nuclear Medicine & Radiopharmaceutical Council.